RESEARCH

Monthly research. One thesis per theme.

Start with a trend — drones, uranium, defense, biotech — and get the small-caps scored for financial stability, not hype. Refreshed monthly.

FILTERED: BIOTECH
All2026AIAI CapexAI HardwareAI InfrastructureAdditive ManufacturingAdvanced ReactorsAerospaceAerospace & DefenseBatteryBeginnerBiotechBiotechnologyCash RunwayChinaConsumer CyclicalCoolingCritical MineralsCryptoCybersecurityData AnalysisData CenterData Center InfrastructureDeep DiveDefenseDroneDronesDrug DiscoveryETFsEdge AIEdge ComputingEducationEnergyEnergy TransitionEnrichmentFiberFuel CellsFuel CycleFundamental AnalysisGenomicsGoldGold MinersGovernanceGridGrowth StocksHALEUHVACHealthcareHow-ToHumanoidHydrogenIndustrialsInfrastructureIoTJune 2026LiDARLithiumMRAMMarket AnalysisMay 2026Medical DevicesMemory & StorageMental HealthMetricsMiningMonthly UpdateNPUNuclearOctober 2026OncologyOptical InterconnectPhotonicsPortfolio ManagementPortfolio StrategyPost-Quantum CryptographyPowerPower & CoolingPre-RevenuePrecious MetalsPsychedelicsQ2 2026QuantumQuantum ComputingRankingsRare DiseaseRisk ManagementRoboticsRoyalty CompaniesSMRSatelliteScore AnalysisScore DistributionScoring SystemSector AnalysisSemiconductorsSensorSeptember 2026Service RoboticsSmall-CapSoftwareSolarSpaceStock AnalysisStock PicksStrategySurgical RoboticsSwitchgearSynthetic BiologyTechTechnologyUAVUraniumUtilitiesValuationaerospaceaiai infrastructureapril 2026automationbiotechconsumercritical mineralsdefenseeVTOLearningseducationenergyfda approvalfundamental analysisgoldguidehealthcareindustrialsinvestinglithiummethodologymetricsminingnuclearquarterlyrare earthrevenue growthroboticsscoringsector analysissemiconductorssmall-capstock analysisstock pickstechnologyuraniumvaluationwatchlistweekly
SHOWINGBiotechClear

FILTERED POSTS

BiotechBiotechnologyRare DiseaseOncologyHealthcareSmall-CapSector AnalysisSeptember 2026

8 Best Small-Cap Biotech Stocks — September 2026

Eight small-cap biotech stocks ranked by our August 30 fundamentals snapshot — profitable rare-disease and specialty franchises, fresh oncology launches, and a Novo-partnered obesity platform.

BiotechSmall-CapFundamental AnalysisHealthcareScore DistributionCash RunwayPre-RevenueData Analysis2026

We Scored 313 Small-Cap Biotechs — 80% Score Below 50. Here's Why That's Correct.

Of 313 small-cap biotechs in our universe, 80% score below 50 and only 7% score 70+. That looks like a model failure. It isn't — the screen is correctly flagging pre-revenue binary-outcome risk. The data, the 7% that pass, and what it means for your watchlist.

AIBiotechDrug DiscoverySmall-CapSector AnalysisMay 2026

4 Best Small-Cap AI Drug Discovery Stocks — May 2026

AI drug discovery splits into three monetization models: software-to-pharma (SDGR), platform-to-partner (ABCL, ABSI), and own-pipeline (RXRX). Each has different unit economics and different bull-case shapes.

Synthetic BiologyBiotechGenomicsSmall-CapSector AnalysisMay 2026

4 Best Small-Cap Synthetic Biology Stocks — May 2026

Synthetic biology as a public small-cap category is mostly the post-SPAC survivors. 4 names with very different business models — organism foundry, antibody engineering, drug-discovery software, and a misclassified med-device.

Mental HealthPsychedelicsBiotechSmall-CapSector AnalysisMay 2026

2 Best Small-Cap Mental Health Tech & Psychedelic Therapeutics Stocks — May 2026

The investable small-cap mental-health-tech and psychedelic-therapeutics universe is sparse. Most psychedelics names are micro-cap or pre-revenue; we have one credible psychedelics developer in our scored universe, plus context on what's missing.

biotechhealthcaresmall-capsector analysis

7 Best Small-Cap Biotech Stocks for 2026 (Cash + Pipeline)

7 small-cap biotech stocks ranked on cash runway, pipeline depth, and balance sheet. April 2026 data — see which are trading below cash.

fda approvalsmall-caphealthcarebiotechstock analysis

BrainSway (BWAY): FDA Clears At-Home Deep TMS

BrainSway (BWAY) gets FDA clearance for at-home Deep TMS depression therapy. Revenue impact, TAM, and our fundamental score breakdown.